TYRA

Tyra Biosciences, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001863127
$26.99 +5.55% $1.6B
17 New Institutional Positions7 Institutional Exits
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders50 funds
Inst. Value$1.4B
Inst. Activity17 buys / 7 sells
Insider Activity0B / 2S
Insider Net $-$595.5K
SEC Reports5
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001863127·Prev Close $25.57

Recent Activity

Jun 12, 2026 short_volume
Short Volume: TYRA — 60.1% short (0.3M / 0.6M)
Short: 332,274 | Exempt: 0 | TRF Vol: 552,472 | Short Ratio: 60.1% | Off-exchange volume (dark pool
May 28, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. was granted 13,160 shares
Director
May 28, 2026 Insider
Verjee Rehan was granted 13,160 shares
Director
May 28, 2026 Insider
Moran Susan was granted 13,160 shares
Director
May 13, 2026 SEC
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R
8-K — Impact 5/10
Apr 20, 2026 SEC
Habib J. Dable, a reporting person at Tyra Biosciences, filed a Form 3 and granted a power of attorney to the company's
3 — Impact 2/10
Apr 17, 2026 SEC
Tyra Biosciences is holding its annual shareholder meeting to elect three directors, including Habib J. Dable, whose rec
DEFA14A — Impact 4/10
Inst.
FMR LLC — DOUBLED
7,747,648 shares ($296.7M)

Price Targets

$51.60 +91.2% upside Strong Buy
Current $26.99 Low $42.00 Median $53.00 High $59.62 11 analysts
$42.00 $59.62

Analyst Ratings

Strong Buy90% buy · 21 analysts
9Strong Buy
10Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 10, 2026 B of A Securities MAINTAIN Buy → Buy
May 19, 2026 Wolfe Research INITIATE Peer Perform
May 14, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Apr 15, 2026 Guggenheim INITIATE Buy
Apr 6, 2026 Canaccord Genuity INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.64 ▼ -11.5% $-0.70 — $-0.56 -36% YoY 14
Next Q $-0.65 ▼ -9.2% $-0.76 — $-0.53 -30% YoY 14
Current FY $-2.57 ▼ -11.0% $-2.87 — $-2.31 -28% YoY 14
Next FY $-2.83 ▼ -10.1% $-3.52 — $-2.26 -10% YoY 14

Latest Reports

MIXED 8-K 5/10
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R
May 13, 2026
NEUTRAL 3 2/10
Habib J. Dable, a reporting person at Tyra Biosciences, filed a Form 3 and granted a power of attorney to the company's
Apr 20, 2026

Top Institutional Holders

FundValueMove
RA CAPITAL MANAGEMENT, L.P.$467.2M—
FMR LLC$296.7MDOUBLED
JANUS HENDERSON GROUP PLC$148.9MADD
FARALLON CAPITAL MANAGEMENT LLC$137.1MADD
BlackRock, Inc.$84.9M—

Recent Insider Trades

DateInsiderTypeValue
May 28, 2026RA CAPITALA$0.00
May 28, 2026Verjee RehanA$0.00
May 28, 2026Moran SusanA$0.00
May 28, 2026Rothenberg StephenA$0.00
May 28, 2026MORE ROBERTA$0.00
50 institutional holders with $1.4B total value (37,719,156 shares) as of 2026-Q1. Top holders: RA, FMR, JANUS. Net buying activity: 17 institutions added/increased vs 7 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1RA CAPITAL MANAGEMENT, L.P.12,198,625$467.2M32.4%—
2FMR LLC7,747,648$296.7M20.5%DOUBLED +61570.4%
3JANUS HENDERSON GROUP PLC3,890,589$148.9M10.3%ADD +32.5%
4FARALLON CAPITAL MANAGEMENT LLC3,580,818$137.1M9.5%ADD +73.3%
5BlackRock, Inc.2,217,929$84.9M5.9%—
6STATE STREET CORP1,216,078$46.6M3.2%ADD +62.3%
7VANGUARD CAPITAL MANAGEMENT LLC1,125,970$43.1M3.0%—
8BARCLAYS PLC833,399$31.9M2.2%—
9JENNISON ASSOCIATES LLC632,432$24.2M1.7%NEW
10GOLDMAN SACHS GROUP INC550,334$21.1M1.5%—
11BALYASNY ASSET MANAGEMENT L.P.351,479$13.5M0.9%TRIM -57.0%
12Woodline Partners LP301,040$11.5M0.8%NEW
13VANGUARD PORTFOLIO MANAGEMENT LLC247,270$9.5M0.7%—
14RAYMOND JAMES FINANCIAL INC247,098$9.5M0.7%—
15BANK OF AMERICA CORP /DE/209,922$8.0M0.6%DOUBLED +448.0%
16CHARLES SCHWAB INVESTMENT MANAGEMENT INC199,111$7.6M0.5%—
17MARSHALL WACE, LLP197,748$7.6M0.5%TRIM -72.2%
18Point72 Asset Management, L.P.180,100$6.9M0.5%NEAR_EXIT -95.6%
19VANGUARD FIDUCIARY TRUST CO157,791$6.0M0.4%—
20Trexquant Investment LP147,317$5.6M0.4%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
FMR LLCDOUBLED12,5637,747,648+61570.4%$296.7M2026-Q1
JANUS HENDERSON GROUP PLCADD2,935,4423,890,589+32.5%$148.9M2026-Q1
FARALLON CAPITAL MANAGEMENT LLCADD2,066,8183,580,818+73.3%$137.1M2026-Q1
STATE STREET CORPADD749,4631,216,078+62.3%$46.6M2026-Q1
JENNISON ASSOCIATES LLCNEW—632,432—$24.2M2026-Q1
BALYASNY ASSET MANAGEMENT L.P.TRIM818,326351,479-57.0%$13.5M2026-Q1
Woodline Partners LPNEW—301,040—$11.5M2026-Q1
BANK OF AMERICA CORP /DE/DOUBLED38,310209,922+448.0%$8.0M2026-Q1
MARSHALL WACE, LLPTRIM711,891197,748-72.2%$7.6M2026-Q1
AMERIPRISE FINANCIAL INCDOUBLED54,625144,900+165.3%$5.5M2026-Q1
WELLINGTON MANAGEMENT GROUP LLPTRIM104,30577,169-26.0%$3.0M2026-Q1
Russell Investments Group, Ltd.DOUBLED12,99670,422+441.9%$2.7M2026-Q1
MANUFACTURERS LIFE INSURANCE COMPANY, THEDOUBLED8,35740,224+381.3%$1.5M2026-Q1
Point72 Asset Management, L.P.NEAR_EXIT874,19238,850-95.6%$1.5M2026-Q1
VOYA INVESTMENT MANAGEMENT LLCADD29,88738,358+28.3%$1.5M2026-Q1
Rafferty Asset Management, LLCDOUBLED15,45534,856+125.5%$1.3M2026-Q1
DEUTSCHE BANK AG\ADD16,37720,495+25.1%$785.0K2026-Q1
STRS OHIODOUBLED70018,100+2485.7%$693.2K2026-Q1
CANADA PENSION PLAN INVESTMENT BOARDTRIM28,90014,300-50.5%$547.7K2026-Q1
ExodusPoint Capital Management, LPTRIM42,79114,066-67.1%$538.7K2026-Q1
Legal & General Group PlcDOUBLED2,3679,537+302.9%$364.8K2026-Q1
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED14,432986,061+6732.5%$37.8K2026-Q1
FEDERATED HERMES, INC.TRIM1,297714-44.9%$27.3K2026-Q1
Rockefeller Capital Management L.P.DOUBLED84421+401.2%$16.1K2026-Q1
FARALLON CAPITAL MANAGEMENT LLCADD1,143,8182,066,818+80.7%$54.3M2025-Q4
14 unique insiders with 24 transactions. Net insider value: -$595.5K ($0.00 bought, $595.5K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 28, 2026RA CAPITAL MANAGEMENT, L.P.DirectorAWARD13,160——
May 28, 2026Verjee RehanDirectorAWARD13,160——
May 28, 2026Moran SusanDirectorAWARD13,160——
May 28, 2026Rothenberg Stephen MichaelDirectorAWARD13,160——
May 28, 2026MORE ROBERT JDirectorAWARD13,160——
May 28, 2026Gulfo Adele M.DirectorAWARD13,160——
May 5, 2026Rueb YuliyaVice President, Finance (PAO)AWARD28,000——
May 5, 2026Rueb YuliyaVice President, Finance (PAO)AWARD8,333——
May 5, 2026Ashar BhaveshChief Operating OfficerAWARD50,295——
May 5, 2026Ashar BhaveshChief Operating OfficerAWARD15,013——
May 5, 2026Harris ToddPresident and CEOAWARD265,000——
May 5, 2026Harris ToddPresident and CEOAWARD79,000——
May 5, 2026Fuhrman AlanChief Financial OfficerAWARD67,000——
May 5, 2026Fuhrman AlanChief Financial OfficerAWARD20,000——
May 5, 2026Warner Douglas JChief Medical OfficerAWARD85,000——
May 5, 2026Warner Douglas JChief Medical OfficerAWARD25,000——
Apr 16, 2026Dable Habib JDirectorAWARD44,400——
Mar 26, 2026KAPLAN GILLADirectorD53,172$37.75$2.0M
Mar 26, 2026KAPLAN GILLADirectorEXERCISE53,172$2.25$119.6K
Mar 25, 2026KAPLAN GILLADirectorEXERCISE14,295$2.25$32.2K
Mar 25, 2026KAPLAN GILLADirectorSELL14,295$36.97$528.5K
Mar 13, 2026Harris ToddPresident and CEOAWARD1,463$9.13$13.4K
Mar 13, 2026Fuhrman AlanChief Financial OfficerAWARD1,376$9.13$12.6K
Feb 12, 2026Bensen DanielChief Discovery OfficerSELL2,128$31.50$67.0K
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 3.2/10.
MIXED 8-K 5/10
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago,
May 13, 2026
NEUTRAL 3 2/10
Habib J. Dable, a reporting person at Tyra Biosciences, filed a Form 3 and granted a power of attorn
Apr 20, 2026
NEUTRAL DEFA14A 4/10
Tyra Biosciences is holding its annual shareholder meeting to elect three directors, including Habib
Apr 17, 2026
NEUTRAL 8-K 3/10
Tyra Biosciences appointed Habib J. Dable to its board of directors as a Class II director, effectiv
Apr 17, 2026
NEUTRAL 144 2/10
Daniel Bensen, an officer of Tyra Biosciences, filed a Form 144 to notify intent to sell up to 8,000
Apr 13, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (90% buy). Based on 21 analysts: 9 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$51.60 mean target +91.2% upside Strong Buy (1.29)
$42.00 Low $59.62 High
MetricValue
Current Price$26.99
Target Low$42.00
Target Mean$51.60
Target Median$53.00
Target High$59.62
# Analysts11
RecommendationStrong Buy (1.29)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.64 $-0.70 $-0.56 -36.2% -11.5% 1↑ 8↓ $0.0B 0.0% 14
Next Q
2026-09-30
 $-0.65 $-0.76 $-0.53 -29.7% -9.2% 2↑ 7↓ $0.0B 0.0% 14
Current FY
2026-12-31
 $-2.57 $-2.87 $-2.31 -27.9% -11.0% 1↑ 7↓ $0.0B 0.0% 14
Next FY
2027-12-31
 $-2.83 $-3.52 $-2.26 -9.9% -10.1% 1↑ 8↓ $0.0B 0.0% 14

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.640
7d ago$-0.639-0.002
30d ago$-0.574-0.066
60d ago$-0.571-0.069
90d ago$-0.566-0.075
11 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 10, 2026 B of A Securities MAINTAIN Buy Buy
May 19, 2026 Wolfe Research INITIATE — Peer Perform
May 14, 2026 HC Wainwright & Co. REITERATE Buy Buy
Apr 15, 2026 Guggenheim INITIATE — Buy
Apr 6, 2026 Canaccord Genuity INITIATE — Buy
Mar 20, 2026 Piper Sandler MAINTAIN Overweight Overweight
Feb 24, 2026 Cantor Fitzgerald INITIATE — Overweight
Feb 17, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Feb 13, 2026 Wedbush MAINTAIN Outperform Outperform
Feb 3, 2026 Oppenheimer MAINTAIN Outperform Outperform
Feb 3, 2026 Jefferies MAINTAIN Buy Buy
Jan 28, 2026 Barclays INITIATE — Overweight
Jan 23, 2026 Piper Sandler MAINTAIN Overweight Overweight
Dec 16, 2025 Wedbush MAINTAIN Outperform Outperform

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202691020090%
May 1, 202691010095%
Apr 1, 20268910094%
Mar 1, 20268910094%
Feb 1, 20267810094%
Jan 1, 20267710093%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 12, 2026
short_volume
Short Volume: TYRA — 60.1% short (0.3M / 0.6M)
Short: 332,274 | Exempt: 0 | TRF Vol: 552,472 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: TYRA — 59.1% short (0.4M / 0.6M)
Short: 352,701 | Exempt: 0 | TRF Vol: 597,064 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: TYRA — 57.2% short (0.4M / 0.6M)
Short: 350,487 | Exempt: 0 | TRF Vol: 612,900 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: TYRA — 59.4% short (0.4M / 0.7M)
Short: 423,912 | Exempt: 310 | TRF Vol: 714,104 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: TYRA — 62.8% short (0.4M / 0.6M)
Short: 377,462 | Exempt: 0 | TRF Vol: 600,870 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
TYRA Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
earnings_calendar
TYRA Q1 2026 Earnings Scheduled — 2026-04-30
Apr 24, 2026
short_volume
Short Volume: TYRA — 57.3% short (0.3M / 0.6M)
Short: 315,524 | Exempt: 0 | TRF Vol: 550,230 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: TYRA — 60.6% short (0.3M / 0.6M)
Short: 345,654 | Exempt: 2,614 | TRF Vol: 569,930 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_interest
FTD: TYRA — 61,808 shares ($2.4M) failed to deliver
Settlement: 20260402, Price: $38.28, FTD Value: $2,366,010.24, TYRA BIOSCIENCES INC COM (DE)
Mar 30, 2026
short_volume
Short Volume: TYRA — 77.3% short (0.7M / 0.8M)
Short: 655,867 | Exempt: 282 | TRF Vol: 848,392 | Short Ratio: 77.3% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_interest
FTD: TYRA — 14,376 shares ($0.5M) failed to deliver
Settlement: 20260323, Price: $37.15, FTD Value: $534,068.4, TYRA BIOSCIENCES INC COM (DE)
Mar 11, 2026
short_interest
FTD: TYRA — 128,036 shares ($4.4M) failed to deliver
Settlement: 20260311, Price: $34.74, FTD Value: $4,447,970.64, TYRA BIOSCIENCES INC COM (DE)
Mar 5, 2026
short_interest
FTD: TYRA — 484,466 shares ($17.1M) failed to deliver
Settlement: 20260305, Price: $35.27, FTD Value: $17,087,115.82, TYRA BIOSCIENCES INC COM (DE)
Feb 9, 2026
short_interest
FTD: TYRA — 63,625 shares ($2.0M) failed to deliver
Settlement: 20260209, Price: $31.00, FTD Value: $1,972,375, TYRA BIOSCIENCES INC COM (DE)